Enzyme and pathway modulation with sulfhydryl compounds and their derivatives

An anti-CD20/anti-CD3 bispecific antibody having monogalactosylated and digalactosylated glycans, the anti-CD20/anti-CD3 bispecific antibody comprising a first antigen binding domain, and a second antigen binding domain, wherein the first antigen binding domain comprises a heavy chain variable domain comprising

• (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:
• 22,
• (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:
• 23, and
• (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:
• 24;
• and
• a light chain variable domain comprising
• (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:
• 25,
• (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:
• 26, and
• (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:
• 27;
• wherein the second antigen binding domain comprises a heavy chain variable domain comprising
• (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:
• 34,
• (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:
• 35, and
• (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:
• 36;
• and
• a light chain variable domain comprising
• (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:
• 37,
• (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:
• 38, and
• (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:
• 39;
• and
• wherein the anti-CD20/anti-CD3 bispecific antibody has 19.0-29.0% (w/w) of monogalactosylated and 1.3-2.8% (w/w) of digalactosylated per total glycan;
• optionally 20.0-28.0% (w/w) of monogalactosylated and 1.4-2.7% (w/w) of digalactosylated per total glycan;
• optionally 21.0-28.0% (w/w) of monogalactosylated and 1.5-2.7% (w/w) of digalactosylated per total glycan and optionally 21.0-27.4% (w/w) of monogalactosylated and 1.5-2.6% (w/w) of digalactosylated per total glycan.